Travere Therapeutics Eulerpool News

Travere Therapeutics Eulerpool News

Travere Therapeutics Stock News

Travere Therapeutics is being monitored by journalists and investors worldwide. We gather the latest Travere Therapeutics news here.

• September 10 ·

  Yahoo
  Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
• September 10 ·

  Thefly.com
  Travere Therapeutics price target raised by $5 at Canaccord, here's why
• September 6 ·

  Thefly.com
  Travere Therapeutics price target raised by $1 at BofA, here's why
• September 6 ·

  Seeking Alpha
  Travere gains on full FDA approval for kidney drug Filspari
• September 5 ·

  Yahoo
  Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
• September 5 ·

  GlobeNewswire
  Travere Therapeutics Announces Full FDA Approval of FILSPARI? (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
• September 5 ·

  Thefly.com
  Travere Therapeutics' Filspari in kidney function granted full approval by FDA
• September 4 ·

  Yahoo
  High Growth Tech Stocks To Watch In September 2024
• September 4 ·

  TipRanks
  Buy Rating Affirmed for Travere Therapeutics Amid Positive KDIGO Guideline Developments and Filspari’s Market Potential
• September 3 ·

  TipRanks
  Travere Therapeutics (TVTX) Gets a Buy from Evercore ISI